低危主动脉瓣狭窄:TAVI与SAVR五年随访荟萃分析
该荟萃分析纳入4项已完成5年随访的低危随机对照试验,共3557例患者(TAVI 1829例,SAVR 1728例)。TAVI与SAVR在全因死亡率及全因死亡或致残性卒中复合终点上无显著差异;TAVI的轻度及以上瓣周漏和永久起搏器植入风险更高,SAVR术后房颤更常见。
要点
- 低危患者5年全因死亡与致残性卒中复合终点TAVI与SAVR无差异
- TAVI增加轻度及以上瓣周漏和永久起搏器植入风险
- SAVR术后房颤发生率高于TAVI
核心结论
- 在已完成5年随访的低危随机对照试验中,TAVI与SAVR在全因死亡率及全因死亡或致残性卒中复合终点上无显著差异。
- TAVI与轻度及以上瓣周漏和永久起搏器植入风险升高相关,而SAVR术后房颤更常见。
研究设计与样本
- 系统检索MEDLINE数据库至2025年5月6日,纳入所有比较TAVI与SAVR且完成5年随访的低危随机对照试验。
- 共纳入4项随机对照试验、3557例患者(TAVI 1829例;SAVR 1728例)。
主要发现
- 全因死亡率无差异(IRR 1.01,95%CI 0.88-1.16,P=0.88)。
- 全因死亡或致残性卒中复合终点无差异(IRR 1.03,95%CI 0.92-1.17,P=0.59)。
- TAVI与轻度及以上瓣周漏风险升高相关(IRR 7.63,95%CI 2.82-20.65,P<0.001)。
- TAVI与永久起搏器植入风险升高相关(IRR 2.12,95%CI 1.5-2.98,P<0.001)。
- TAVI与术后房颤风险降低相关(IRR 0.44,95%CI 0.28-0.71,P<0.001)。
临床怎么用
- 对低危主动脉瓣狭窄患者,5年死亡与致残性卒中结局TAVI与SAVR相当,选择术式时需权衡瓣周漏与起搏器风险及房颤风险。
- TAVI患者应关注瓣周漏和永久起搏器植入风险,SAVR患者应关注术后房颤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Transcatheter aortic valve implantation (TAVI) has shown similar short-term outcomes when compared to surgical aortic valve replacement (SAVR) in randomized controlled trials (RCTs). Longer-term outcomes for low-risk cohorts are now emerging. Here, we analyse all low-risk TAVI versus SAVR RCTs that completed 5-year follow-up. METHODS: A systematic MEDLINE database search was conducted through 6 May 2025, identifying all low-risk RCTs comparing TAVI with SAVR that had completed 5-year follow-up. The primary outcomes were all-cause mortality and the composite of all-cause mortality or disabling stroke. Secondary outcomes included stroke, cardiovascular death, aortic reintervention, myocardial infarction, paravalvular leak, need for permanent pacemaker and postprocedural atrial fibrillation. RESULTS: Four RCTs, including 3557 patients (TAVI: 1829; SAVR: 1728), were analysed. There was no difference between cohorts in all-cause mortality [incidence rate ratio (IRR) 1.01, 95% confidence interval (CI): 0.88-1.16, P = 0.88] or the composite of all-cause mortality or disabling stroke (IRR 1.03, 95% CI: 0.92-1.17, P = 0.59). TAVI was associated with increased risk of mild or greater paravalvular leak (IRR 7.63, 95% CI: 2.82-20.65, P < 0.001) and permanent pacemaker implantation (IRR 2.12, 95% CI: 1.5-2.98, P < 0.001) and a decreased risk of postprocedural atrial fibrillation (IRR 0.44, 95% CI: 0.28-0.71, P < 0.001). CONCLUSIONS: In published RCTs of low-risk cohorts with completed 5-year follow-up, there was no significant difference between TAVI and SAVR neither in overall mortality nor in the composite of mortality and stroke. Valve-related events (paravalvular leaks and pacemaker need) were higher with TAVI, while atrial fibrillation was more common with SAVR.
引用
- Doenst T, Gregg AC, Kirov H, et al. Surgical versus transcatheter treatment of aortic valve stenosis-a meta-analysis of low-risk randomized trials with completed 5-year follow-up. Eur J Cardiothorac Surg. 2025. PMID: 40580456. doi:10.1093/ejcts/ezaf215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。